Mpox (formerly monkeypox): pathogenesis, prevention, and treatment
Abstract In 2022, a global outbreak of Mpox (formerly monkeypox) occurred in various countries across Europe and America and rapidly spread to more than 100 countries and regions. The World Health Organization declared the outbreak to be a public health emergency of international concern due to the...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2023-12-01
|
| Series: | Signal Transduction and Targeted Therapy |
| Online Access: | https://doi.org/10.1038/s41392-023-01675-2 |
| _version_ | 1797371167152013312 |
|---|---|
| author | Junjie Lu Hui Xing Chunhua Wang Mengjun Tang Changcheng Wu Fan Ye Lijuan Yin Yang Yang Wenjie Tan Liang Shen |
| author_facet | Junjie Lu Hui Xing Chunhua Wang Mengjun Tang Changcheng Wu Fan Ye Lijuan Yin Yang Yang Wenjie Tan Liang Shen |
| author_sort | Junjie Lu |
| collection | DOAJ |
| description | Abstract In 2022, a global outbreak of Mpox (formerly monkeypox) occurred in various countries across Europe and America and rapidly spread to more than 100 countries and regions. The World Health Organization declared the outbreak to be a public health emergency of international concern due to the rapid spread of the Mpox virus. Consequently, nations intensified their efforts to explore treatment strategies aimed at combating the infection and its dissemination. Nevertheless, the available therapeutic options for Mpox virus infection remain limited. So far, only a few numbers of antiviral compounds have been approved by regulatory authorities. Given the high mutability of the Mpox virus, certain mutant strains have shown resistance to existing pharmaceutical interventions. This highlights the urgent need to develop novel antiviral drugs that can combat both drug resistance and the potential threat of bioterrorism. Currently, there is a lack of comprehensive literature on the pathophysiology and treatment of Mpox. To address this issue, we conducted a review covering the physiological and pathological processes of Mpox infection, summarizing the latest progress of anti-Mpox drugs. Our analysis encompasses approved drugs currently employed in clinical settings, as well as newly identified small-molecule compounds and antibody drugs displaying potential antiviral efficacy against Mpox. Furthermore, we have gained valuable insights from the process of Mpox drug development, including strategies for repurposing drugs, the discovery of drug targets driven by artificial intelligence, and preclinical drug development. The purpose of this review is to provide readers with a comprehensive overview of the current knowledge on Mpox. |
| first_indexed | 2024-03-08T18:15:54Z |
| format | Article |
| id | doaj.art-b9b45f41a1f847e4a4aa1c9b5dbcd0f3 |
| institution | Directory Open Access Journal |
| issn | 2059-3635 |
| language | English |
| last_indexed | 2024-03-08T18:15:54Z |
| publishDate | 2023-12-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Signal Transduction and Targeted Therapy |
| spelling | doaj.art-b9b45f41a1f847e4a4aa1c9b5dbcd0f32023-12-31T12:16:01ZengNature Publishing GroupSignal Transduction and Targeted Therapy2059-36352023-12-018111510.1038/s41392-023-01675-2Mpox (formerly monkeypox): pathogenesis, prevention, and treatmentJunjie Lu0Hui Xing1Chunhua Wang2Mengjun Tang3Changcheng Wu4Fan Ye5Lijuan Yin6Yang Yang7Wenjie Tan8Liang Shen9Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and ScienceXiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and ScienceXiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and ScienceXiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and ScienceNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and PreventionXiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and ScienceCollege of Biotechnology, Tianjin University of Science & TechnologyShenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for infectious disease, State Key Discipline of Infectious Disease, Shenzhen Third People’s Hospital, Second Hospital Affiliated to Southern University of Science and TechnologyNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and PreventionXiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and ScienceAbstract In 2022, a global outbreak of Mpox (formerly monkeypox) occurred in various countries across Europe and America and rapidly spread to more than 100 countries and regions. The World Health Organization declared the outbreak to be a public health emergency of international concern due to the rapid spread of the Mpox virus. Consequently, nations intensified their efforts to explore treatment strategies aimed at combating the infection and its dissemination. Nevertheless, the available therapeutic options for Mpox virus infection remain limited. So far, only a few numbers of antiviral compounds have been approved by regulatory authorities. Given the high mutability of the Mpox virus, certain mutant strains have shown resistance to existing pharmaceutical interventions. This highlights the urgent need to develop novel antiviral drugs that can combat both drug resistance and the potential threat of bioterrorism. Currently, there is a lack of comprehensive literature on the pathophysiology and treatment of Mpox. To address this issue, we conducted a review covering the physiological and pathological processes of Mpox infection, summarizing the latest progress of anti-Mpox drugs. Our analysis encompasses approved drugs currently employed in clinical settings, as well as newly identified small-molecule compounds and antibody drugs displaying potential antiviral efficacy against Mpox. Furthermore, we have gained valuable insights from the process of Mpox drug development, including strategies for repurposing drugs, the discovery of drug targets driven by artificial intelligence, and preclinical drug development. The purpose of this review is to provide readers with a comprehensive overview of the current knowledge on Mpox.https://doi.org/10.1038/s41392-023-01675-2 |
| spellingShingle | Junjie Lu Hui Xing Chunhua Wang Mengjun Tang Changcheng Wu Fan Ye Lijuan Yin Yang Yang Wenjie Tan Liang Shen Mpox (formerly monkeypox): pathogenesis, prevention, and treatment Signal Transduction and Targeted Therapy |
| title | Mpox (formerly monkeypox): pathogenesis, prevention, and treatment |
| title_full | Mpox (formerly monkeypox): pathogenesis, prevention, and treatment |
| title_fullStr | Mpox (formerly monkeypox): pathogenesis, prevention, and treatment |
| title_full_unstemmed | Mpox (formerly monkeypox): pathogenesis, prevention, and treatment |
| title_short | Mpox (formerly monkeypox): pathogenesis, prevention, and treatment |
| title_sort | mpox formerly monkeypox pathogenesis prevention and treatment |
| url | https://doi.org/10.1038/s41392-023-01675-2 |
| work_keys_str_mv | AT junjielu mpoxformerlymonkeypoxpathogenesispreventionandtreatment AT huixing mpoxformerlymonkeypoxpathogenesispreventionandtreatment AT chunhuawang mpoxformerlymonkeypoxpathogenesispreventionandtreatment AT mengjuntang mpoxformerlymonkeypoxpathogenesispreventionandtreatment AT changchengwu mpoxformerlymonkeypoxpathogenesispreventionandtreatment AT fanye mpoxformerlymonkeypoxpathogenesispreventionandtreatment AT lijuanyin mpoxformerlymonkeypoxpathogenesispreventionandtreatment AT yangyang mpoxformerlymonkeypoxpathogenesispreventionandtreatment AT wenjietan mpoxformerlymonkeypoxpathogenesispreventionandtreatment AT liangshen mpoxformerlymonkeypoxpathogenesispreventionandtreatment |